Cover Image

Aseptic HLA B27-positive spondylodiscitis: decreased 18F-FDG uptake after etanercept treatment

M. Benucci, A. Damiani, A. Arena, M. Infantino, M. Manfredi, F. Li Gobbi
  • A. Damiani
    Rheumatology Unit, S. Giovanni di Dio Hospital, Firenze, Italy
  • A. Arena
    Nuclear Medicine Unit, New Hospital, Prato, Italy
  • M. Infantino
    Immunology and Allergology Laboratory Unit, S. Giovanni di Dio Hospital, Firenze, Italy
  • M. Manfredi
    Immunology and Allergology Laboratory Unit, S. Giovanni di Dio Hospital, Firenze, Italy
  • F. Li Gobbi
    Rheumatology Unit, S. Giovanni di Dio Hospital, Firenze, Italy

Abstract

We observed a 69-year old man suffering from HLA B27 ankylosing spondylitis with persistent night back pain. 18F-FDG-PET/CT showed an increased metabolism at the level of the spinal space of L2-L3, L3-L4 with increased uptake compatible with spondylodiscitis. He started therapy with etanercept 50 mg/week. After six months of treatment repeated testing showed no uptake of the discs and vertebral bodies.

Keywords

Spondylodiscitis; etanercept; ankylosing spondylitis.

Full Text:

PDF
Submitted: 2016-07-17 19:09:51
Published: 2016-12-16 11:20:55
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
1302

Views:
PDF
255

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2016 M. Benucci, A. Damiani, A. Arena, M. Infantino, M. Manfredi, F. Li Gobbi

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2017     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185